BL-4020 was developed by Professor Hillel Berkovier and Dr. Ayelet Bernholtz from the Hebrew University of Jerusalem and Professor Yonatan Gershoni from Tel Aviv University
Beauline R. X., a leading drug development company, announced today the signing of an exclusive licensing agreement with the Research and Development Implementation Company of the Hebrew University of Jerusalem, one of the world's leading companies for commercializing technologies, and Ramot Company at Tel Aviv University, the company for commercializing technologies of Tel Aviv University, for the development and commercialization of - BL-4020, a small protein for the treatment of inflammatory diseases. After signing this agreement, the company's drug pipeline includes 13 drugs, 3 of which are in clinical development stages.
BL-4020 is a peptide designed to function as an anti-inflammatory drug for a variety of inflammatory diseases such as asthma and colitis. The peptide mimics a protein called ManLAM found on the TB bacteria cell membrane. This protein is responsible for regulating the immune system and suppresses a variety of inflammatory diseases. BL-4020 preserves the anti-inflammatory properties of ManLAM, and is expected to be effective and have a high level of safety. In preclinical trials conducted at the Hebrew University, BL-4020 was found to be effective in a variety of animal models for inflammatory diseases such as asthma and colitis.
"Inflammation is the cause of many serious diseases and we believe that BL-4020, based on a unique mechanism of action, has the potential to be an effective and safe drug," said Dr. Maurice Lester, CEO of Bioline R. Ex. "BL-4020 is a promising addition to our pipeline of innovative drugs, and we are happy about the continued fruitful collaboration with the Hebrew University and Tel Aviv University."
BL-4020 was developed by Professor Hillel Berkovier and Dr. Ayelet Bernholtz from the Hebrew University of Jerusalem and Professor Yonatan Gershoni from Tel Aviv University. In the intention of Oline R. Ex. Submit an application for financing the development of the projects by the National Biotechnology Grant received from the Office of the Chief Scientist, through Bioline Innovations Jerusalem Sh.M.
Nava Savretsky-Sofer, President and CEO of Apisil, added, "The invention of Professors Berkovier and Gershoni and Dr. Bernholtz holds the promise of a significant improvement in the health of patients with various inflammatory diseases. We are happy to team up again with Beauline R. Ex. Because they have the resources and capabilities to exhaust the promise inherent in this molecule."
Currently, the treatment of inflammatory diseases is mainly with the help of steroids or non-steroidal anti-inflammatory drugs, both of which can have serious side effects. Steroids can cause hormonal imbalance, calcium leakage, stomach ulcers, mood swings and a variety of other problems. Over time, non-steroidal drugs can cause gastrointestinal problems, and are associated with 20% to 30% of hospitalizations and deaths due to gastric ulcers in patients 65 and older. BL-4020 is expected to be a promising treatment for a number of inflammatory diseases, which are currently treated with steroids and non-steroidal drugs, without the side effects that characterize these drugs.
5 תגובות
A week after the new team takes off to the station, and besides, what's the deal with Bioline? Just one comment earlier you apologized for asking an irrelevant question.
Avi Bilovski I simply have a question that is not on the site when the 14th crew of the station will return to Earth
Sorry
I don't have enough manpower to handle all the news. My apologies, and again I ask not to write comments that are not relevant to the topic of the article.
New Arizona's Lavi Bilovsky sent more images from Jupiter